Serum Institute of India to Produce up to 100 Million COVID-19 Vaccine Doses

SERUM INSTITUTE OF INDIA TO PRODUCE UP TO 100 MILLION COVID-19 VACCINE DOSES FOR INDIA AND LOW- AND MIDDLE-INCOME COUNTRIES AS EARLY AS 2021

• New landmark collaboration between the Serum Institute of India (SII), Gavi, and Bill & Melinda Gates Foundation

• “The Bill & Melinda Gates Foundation”, via its Strategic Investment Fund, will provide at- risk funding of US$150 million to Gavi. And the funding will get used to support the SII to manufacture the potential vaccine candidates.

• Price of the vaccine will be maximum US$3 per dose and will be available to the 92 countries included in Gavi’s COVAX Advance Market Commitment (AMC)

The world’s largest vaccine manufacture

Serum Institute of India (SII), has entered into a new landmark partnership with Gavi. The Vaccine Alliance and the Bill & Melinda Gates Foundation, to accelerate the manufacture. The delivery of up to 100 million doses of COVID-19 vaccines will also get speed up for India and low- and middle-income countries.

Adar Poonawalla shared this news via his tweet:

I would like to thank @BillGates, @gatesfoundation, @GaviSeth for this key partnership of risk sharing and manufacturing of a 100 million doses, which will also ensure equitable access at an affordable price to many countries around the world. https://t.co/NDmpo23Ay8 pic.twitter.com/jNaNh6xUPy

— Adar Poonawalla (@adarpoonawalla) August 7, 2020

The Bill & Melinda Gates Foundation, via its Strategic Investment Fund, will provide at-risk funding of US$150 million to Gavi. And it will get used to support the Serum Institute of India to manufacture potential vaccine candidates, and for future procurement of vaccines for low- and middle-income countries via Gavi’s COVAX AMC.

The press release is available as an official announcement by Serum Institute of India on their Facebook page.

Also Read – Business Challenges and Opportunities in COVID-19